howclose.to
Biology & Health · Updated July 2026Momentum · steady ↔

How close are we to a vaccine in 100 days?Can we beat the next pandemic in 100 days?

or, simply: Can we beat the next pandemic in 100 days?or, precisely: How close are we to a vaccine in 100 days?

COVID compressed vaccine development from years to months; the goal is a repeatable 100 days from a new pathogen to authorized shots.COVID took 326 days. The target for the next pandemic is 100 - a vaccine before the outbreak spirals.

We are here

Platforms advance, mission unproven - CEPI reports 75+ supported candidates and platforms, with Lassa, Nipah and MERS vaccines in Phase II, but no 100-day authorization. Next up - CEPI 3.0 begins (expected 2027).

01 · Where we stand

State of playWhere 100-day vaccines stands right now

The current stage, the honest metric, and the single threshold that gates the next stage. Each threshold is a falsifiable claim with a named next test.How far up the ladder we've climbed, the honest verdict, and the one thing blocking the next step.

The five stagesMaturity ladder
Deployed
Out in the real worldDeployed at scale
Scaling
Making it cheap enough at scaleScaling toward competitive cost
Engineering← HERE
Building one that pays for itselfEngineering a system that pays back
Lab demo
Shown to work in a labDemonstrated in the laboratory
Theoretical
The idea is worked out on paperTheoretical basis established
The honest verdictVerified state

COVID took 326 days. The target for the next pandemic is 100 - a vaccine before the outbreak spirals.COVID compressed vaccine development from years to months; the goal is a repeatable 100 days from a new pathogen to authorized shots.

153Best result so farNovel H1N1: first US detection April 15 to FDA approvals September 15
100CEPI and G7 100 Days Mission
Blocking the next stepBlocking threshold

Prepare before the outbreakResponse-Ready Prototype Library Next test: CEPI 3.0 must publish viral-family coverage and demonstrate that a stored prototype can accelerate a novel related-virus response.

The verdict, in five rungsHow far up the ladder↓ next — the thresholds & the gap
01 · The evidence

The thresholds that gate the next stageWhat has to happen next

Each threshold is a falsifiable claim with a named next test; the gap chart shows how far today's metric sits from the goal.Each row is one thing that has to be proven — and how far today's number is from the target.

Rapid Platform-to-Clinic TranslationDesign and test quickly✓ Achieved · Mar 2020
100%
Proven byNIH and Moderna dosed the first Phase I participant on day 66, proving rapid clinical entry but not authorization.
Response-Ready Prototype LibraryPrepare before the outbreakIn progress
55%
Next testCEPI 3.0 must publish viral-family coverage and demonstrate that a stored prototype can accelerate a novel related-virus response.
Authorization Within 100 DaysApprove within 100 daysEarly
31%
Next testThe next qualifying outbreak must reach authorization by day 100 with prospectively defined safety, efficacy and manufacturing evidence.
Manufacturing and Equitable DeliveryMake doses everywhereEarly
35%
Next testBy 2031 CEPI partners must document access to 1-2 billion doses of usable capacity and test activation, allocation and cross-border release.
THRESHOLDS - Thresholds for 100-Day Vaccines.
Scale
Days from threat identification to initial vaccine authorization over time, with measured values, projected values, and a goal at 100 days.050100150200250300350Days from threat identification to initial vaccine auth… · daysYear20092020GOAL 100 · CEPI and G7 100 Days MissionNovel H1N1: first US detect…COVID-19: genome release Ja…~226 days to goal
NOTE - This is the candidate file's recommended headline metric, but the two observations are not an apples-to-apples technology curve. The 2009 H1N1 vaccines used established seasonal-influenza plants and strain-change regulatory supplements; COVID-19 required a new coronavirus product and large efficacy trials. Both points stop at first authorization or rollout and therefore exclude the additional time required for mass manufacturing, allocation and population coverage.
02 · How we got here

The record behind the verdict

Major events set large; context events set small but never hidden. Everything below the TODAY rule is a schedule, not a result.

1796-19322 events1 shown

Learning to Induce Immunity

Learning to Induce Immunity moved the field from jenner tests cowpox protection to pasteur prevents rabies. The results narrowed the next question without closing it.

1796
Jenner tests cowpox protectionExperiment
Edward Jenner inoculated eight-year-old James Phipps with cowpox and later showed protection against smallpox.
Edward Jenner
1885
Pasteur prevents rabies
Louis Pasteur gave Joseph Meister a course of 13 post-exposure injections; Meister survived rabies exposure.
Louis Pasteur and colleagues
1933-19602 events1 shown

Vaccines Become Industrial

Vaccines Become Industrial moved the field from influenza virus isolated to flu vaccine licensed. The results narrowed the next question without closing it.

1961-20167 events4 shown

Programmable Platforms Emerge

Programmable Platforms Emerge moved the field from messenger rna defined to ebola vaccines arrive late. The results narrowed the next question without closing it.

1976
Swine-flu campaign haltedSetback
After over 40 million vaccinations, officials paused the campaign over roughly one excess GBS case per 100,000 recipients.
US federal health agencies
1990
Injected mRNA makes protein
Researchers showed in-vitro-transcribed mRNA could direct protein production after injection into mouse muscle.
University of Wisconsin researchers
2005
Modified mRNA reduces inflammationExperiment
Karikó and Weissman showed modified nucleosides suppressed unwanted inflammatory sensing and enabled greater protein production.
Katalin Karikó and Drew Weissman
2009
H1N1 vaccines approvedDeployment
FDA approved four vaccines 153 days after first detection, using strain-change supplements to established influenza licenses.
FDA and four vaccine manufacturers
2014
Ebola vaccines arrive lateSetback
The 2013-2016 West African epidemic killed more than 11,300 people before an efficacy trial established vaccine protection.
WHO and West African health systems
2017-20202 events0 shown

Preparedness Meets a Pandemic

Preparedness Meets a Pandemic moved the field from cepi launches at davos to first ebola vaccine licensed. The results narrowed the next question without closing it.

2019
First Ebola vaccine licensed
FDA approved Ervebo, the first licensed vaccine against disease caused by Zaire ebolavirus.
Merck and US FDA
2021-203113 events2 shown

The Hundred-Day Mission

The Hundred-Day Mission moved the field from curevac misses efficacy bar to cepi 3.0 begins. The results narrowed the next question without closing it.

2021
CureVac misses efficacy bar
CureVac's first-generation mRNA candidate reported 48% efficacy in its Phase 2b/3 final analysis.
CureVac
2023
First self-amplifying mRNA vaccine approved
Japan approved ARCT-154, validating an RNA platform designed to obtain more antigen expression from a smaller dose; it was not a 100-day Disease X response.
Arcturus Therapeutics, CSL and Meiji Seika Pharma
2024
WHO prequalifies first mpox vaccine
MVA-BN prequalification enabled UN procurement during the African emergency, but accelerated deployment of an existing vaccine rather than development of a new one.
World Health Organization and Bavarian Nordic
2025
FDA suspends live chikungunya vaccine
FDA suspended IXCHIQ's licence after serious chikungunya-like adverse events, including a vaccine-strain-positive fatal encephalitis case, while clinical benefit remained unconfirmed.
US Food and Drug Administration and Valneva
2026
Korea tests the 100-day pathway
A national tabletop exercise simulated detection, trials, manufacture, regulation and licensure for a fictional novel virus; it tested coordination, not vaccine performance.
Korean health agencies, CEPI, IVI and industry
2026
Platforms advance, mission unprovenExperimentWe are here
CEPI reports 75+ supported candidates and platforms, with Lassa, Nipah and MERS vaccines in Phase II, but no 100-day authorization.
CEPI and partner developers
2027
CEPI 3.0 beginsFundingTarget
CEPI's 2027-2031 strategy is scheduled to begin with a $3.6 billion plan, of which $2.5 billion was still being sought in 2026.
CEPI and funders
2020-20314 events3 shown

Events outside the declared eras

Events outside the declared eras moved the field from coronavirus genome released to distributed capacity target matures. The results narrowed the next question without closing it.

2031
Distributed capacity target maturesDeploymentTarget
CEPI targets access to 1-2 billion vaccine doses of regional manufacturing capacity across multiple technologies by end-2031.
CEPI and regional manufacturing partners
— end of record · 30 shown, 0 hidden —
30 events · below the TODAY rule = scheduled, not done
03 · The data behind the verdict

Why the meters read the way they do

The learning curves and comparisons that justify each threshold's percentage. Every series is measured, with the source event linked in the timeline above.

Fast to clinic. Slow to authorisation.COVID dose-1 in 326 days vs the 100-day goal; authorisation lagged at 343 days.Twin lane = H1N1 vs COVID-19 milestones · days from detection or genome release · 2009–2020 · fewer is closerTwin lane = H1N1 vs COVID-19 milestones · one mark = one observed milestone in days from detection or genome release · 2009–2020 · the 100-day rail is a goal, not an achievement
Historical vaccine response times on a countdown trackThe chart compares H1N1 and COVID-19 response milestones against a 100-day goal. H1N1 is grey and COVID-19 is accent ink. The decisive COVID-19 human-trial milestone occurred at day 66; the latest response point is 326 days.100-DAY GOAL400d100d0dH1N1 milestones153d · authorised173d · first US doses247d · 100m availableCOVID-19 milestones66d · first human trial326d · first rollout343d · US EUAH1N1 · 153dCOVID-19 · 326dDECISIVE OBSERVED MOMENT66 DAYS · FIRST HUMAN TRIAL226 days to closeDays from threat identification to authorization · fewer is closer
CDC · CEPI · FDA · NIH · AS OF JUL 2026
Global procurement eventually reached enormous scale, but the first African shipment came 74 days after initial rollout and the 2026 value is CEPI's rounded 'nearly 2 billion' total.
Global procurement eventually reached enormous scale, but the first African shipment came 74 days after initial rollout and the 2026 value is CEPI's rounded 'nearly 2 billion' total.1101001,000COVAX cumulative delivered doses · million dosesYear2021202220262,000 million doses
NOTE - Global procurement eventually reached enormous scale, but the first African shipment came 74 days after initial rollout and the 2026 value is CEPI's rounded 'nearly 2 billion' total.
Manufacturing and delivery scale increased dramatically, but the points cover different populations, time windows and products and should not be treated as a productivity curve.
Manufacturing and delivery scale increased dramatically, but the points cover different populations, time windows and products and should not be treated as a productivity curve.1001,000Selected emergency vaccination campaign scale · million doses or people vaccinatedYear1976201020226,400 million doses or people vaccinated
NOTE - Manufacturing and delivery scale increased dramatically, but the points cover different populations, time windows and products and should not be treated as a productivity curve.
  • COVID-19 first rollout326 days
  • Mission target100 days
COMPARISON - COVID-19's record vaccine rollout was still more than three times the 100-day objective.
  • High-income countries50 % of adults, approximately
  • Most low-income countries2 % of adults, less than
COMPARISON - By August 2021, adult full-vaccination coverage differed by more than 25-fold between income groups.
  • People vaccinated40 million, more than
  • Additional GBS risk1 case per 100,000 vaccinees
COMPARISON - The 1976 campaign vaccinated over 40 million people despite detecting an excess GBS risk near one per 100,000 recipients.
  • 2009 H1N1 first deployment20 weeks
  • Typical large-scale flu production26 weeks, approximately
COMPARISON - The H1N1 platform produced first deployable vaccines in 20 weeks versus roughly 26 weeks for traditional seasonal scale-up.
Technical notes

Read the evidence more closely

Definitions, system boundaries and experimental caveats behind the headline record.

01What the 100-day target includes

The target is not merely “design in 100 days”: CEPI defines it as a safe, effective vaccine ready for initial authorization and manufacturing at scale within 100 days of threat recognition.

Source · CEPI
02What ARCT-154 demonstrated

ARCT-154 carries replicase instructions that amplify its RNA inside cells; it does not create an infectious, self-propagating virus. In an 828-person randomized booster trial, day-28 ancestral-strain neutralizing GMTs were 5,641 versus 3,934 for BNT162b2, a GMT ratio of 1.43. These immunogenicity results do not establish faster Disease X authorization.

Source · The Lancet Infectious Diseases
03What enabled Rwanda’s ten-day start

Rwanda’s ten-day Marburg result depended on prior Phase I data, manufactured doses and a pre-agreed WHO protocol. More than 1,700 high-risk people had been vaccinated by the end of October 2024, but the open-label study lacked a negative-control arm and could not robustly estimate efficacy.

Source · npj Vaccines
04MVA-BN was reviewed, not newly developed

WHO’s MVA-BN prequalification followed review by the EMA rather than fresh vaccine development. WHO estimated pre-exposure effectiveness at 76% for one dose and 82% for two, while requesting continued evidence collection.

Source · WHO
05Why 100 days needs new evidence paths

A published process analysis concluded that applying known COVID-era best practices would compress a comparable development programme only to roughly 250 days; reaching 100 days would probably require validated immune correlates that permit initial authorization before conventional disease-endpoint efficacy data mature.

Source · New England Journal of Medicine
06The pipeline is not converting late-stage

The 2024 readiness scorecard found early pipeline activity but little late-stage conversion: seven priority-pathogen vaccines entered Phase I, only one advanced to Phase III, and non-COVID diagnostics, therapeutics and vaccine R&D funding had fallen 31% from 2022 to 2023.

Source · International Pandemic Preparedness Secretariat
04 · What it unlocks

If the remaining tests pass

Downstream capabilities, drawn dashed because they depend on results not yet in.

100-Day VaccinesOutbreak containment before global spreadInitial high-risk groups could be protected while an outbreak is still geographically limited rather than after worldwide transmission.Reusable vaccine factoriesValidated platforms and plants could switch antigen instructions without rebuilding the production process for every pathogen.Smaller social and economic shocksEarlier protection could reduce reliance on prolonged border closures, business restrictions and emergency hospital expansion.
05 · The players & the money

Who is building it-and what the money saysCapital, institutions and the global race

The teams doing the work, where they are based, and whether the money points to real delivery or only a plan.Company finance, public programmes, institutional leadership and market evidence-kept separate from valuations, forecasts and announced capacity.

The short versionCapital and institutional readout

Rapid vaccine response is an international systems problem: adaptable platforms matter, but so do pre-positioned trials, assays, regulators, manufacturing inputs and distribution. The 100 Days Mission is still a target. Current funding and capacity figures describe preparedness infrastructure, not a vaccine proven safe, effective and equitably deployed inside 100 days.

Players

Who is building itCompanies, laboratories and programmes

CEPI

Global

Coordinates vaccine platforms, pathogen-family R&D and preparedness networks around the 100 Days Mission

BioNTech

Germany / Rwanda

mRNA platform developer and operator of the BioNTainer manufacturing site in Kigali

Sabin Vaccine Institute

USA / Rwanda

Develops a Marburg vaccine candidate and supplied Rwanda's rapid outbreak-response trial

Companies, laboratories and programmes working on this problem
PlayerCountryWhat they are doingFundingNamed investorsSource
CEPInonprofitGlobal

Coordinates vaccine platforms, pathogen-family R&D and preparedness networks around the 100 Days Mission

Seeking $2.5B in new funding for 2027-2031; this is not money already raised.

Not disclosedNot disclosedSource · cepi.net
BioNTechcompanyGermany / Rwanda

mRNA platform developer and operator of the BioNTainer manufacturing site in Kigali

The commitment advances the Kigali facility; output remains product- and authorization-dependent.

CEPI commitment · up to $145M · Oct 2025CEPISource · biontech.com
Sabin Vaccine InstitutenonprofitUSA / Rwanda

Develops a Marburg vaccine candidate and supplied Rwanda's rapid outbreak-response trial

Rapid trial activation demonstrated logistics, not vaccine efficacy.

Not disclosedNot disclosedSource · sabin.org
International Vaccine InstitutenonprofitRepublic of Korea

Provides technical services for epidemic-vaccine development and trial readiness

Not disclosedNot disclosedSource · ivi.int
Africa CDC / PAVMgovernmentAfrican Union

Coordinates regional vaccine-manufacturing capacity, procurement and market shaping

60% local production is a 2040 target, not current output.

Not disclosedNot disclosedSource · africacdc.org
EU HERAgovernmentEuropean Union

Maintains emergency countermeasure preparedness, procurement and EU FAB surge manufacturing

Not disclosedNot disclosedSource · commission.europa.eu
06 · Sources

Where every number comes from

14 sources — every figure on this page traces to one.

  1. CEPI 100 Days Missioncepi.net
  2. CEPI progress and resultscepi.net
  3. CEPI 3.0 strategystatic.cepi.net
  4. CEPI 3.0 investment casestatic.cepi.net
  5. G7 100 Days Mission implementation reportgov.uk
  6. CDC 2009 H1N1 pandemic timelinearchive.cdc.gov
  7. WHO pandemic influenza manufacturing timelinewho.int
  8. NIH first mRNA-1273 trial reportnih.gov
  9. Nobel committee mRNA-vaccine scientific backgroundnobelprize.org
  10. WHO history of influenza vaccinationwho.int
  11. CDC historical vaccine-safety concernscdc.gov
  12. FDA Ervebo approval recordfda.gov
  13. WHO first COVAX shipmentwho.int
  14. WHO COVID-19 vaccine-equity statementwho.int